Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For people who have CV19 or their family members see below the first is for severe cases and the second is moderate.
Phase 2b/3 Trial for Patients with Severe or Critical Coronavirus Disease:
For information about enrolling in our Phase 2b/3 trial for patients with Severe or Critical Coronavirus disease, please contact:
Montefiore Medical Center
New Patient Coordinators:
Pam Philippsborn at (718) 920-5864
Reena Joseph at (718) 920 5864
Jasmine Thalappillil at (718) 920-5864
Patient referrals directly to:
Harish Seethamraju, M.D.
Main telephone: (718) 920-5864
3400 Bainbridge Avenue
Bronx, NY 10467
Novant Health
New Patient Coordinators:
Kathleen O’Brien kathleen.obrien@novanthealth.org (704) 996-7627
Pailing Richards pcrichards@novanthealth.org (704) 996-7627
Patient referrals directly to:
Michael Morgan, M.D.
Main telephone: (336) 718-0440
1381 Westgate Center Dr
Winston-Salem, NC 27103
UCLA Medical Center
New Patient Coordinator:
Nancy Lopez NancyRLopez@mednet.ucla.edu (310) 794-8043
Patient referrals directly to:
Otto Yang, M.D.
Main telephone: (310) 206-7663
200 Medical Plaza Driveway
Los Angeles, CA 90095
Baylor Scott & White Health
New Patient Coordinator:
Samantha Wang samantha.wang@bswhealth.org (214) 818-2526
Patient referrals directly to:
Uriel Sandkovsky, M.D.
Main telephone: (214) 823-2533
3409 Worth St, Suite 710
Dallas, TX 75246
University of Texas Health
New Patient Coordinator:
Jordan Lake, M.D., M.Sc. jordan.e.lake@uth.tmc.edu (713) 500-6767
Patient referrals directly to:
Jordan Lake, M.D., M.Sc.
Main telephone: (713) 500-6767
7000 Fannin St, Suite 1200
Houston, TX 77030
Beth Israel Deaconess Medical Center - Harvard Medical School
New Patient Coordinator:
Caitlin Davis cdavis6@bidmc.harvard.edu (617) 735-4466
Patient referrals directly to:
Chen S. Tan, M.D.
Main telephone: (617) 632-7706
110 Francis Street, Lowry GB
Boston, MA 02215-5501
St. Barnabas Medical Center
New Patient Coordinator:
Sara Ingersoll sara.ingersoll@rwjbh.org (973) 322-2527
Patient referrals directly to:
Subroto Paul, M.D., M.P.H.
Main telephone: (973) 322-6757
101 Old Short Hills Road, Suite 302
West Orange, NJ 07052
Atlantic Health
New Patient Coordinator:
Kathryn Radler kathryn.radler@atlantichealth.org (908) 522-4899
Patient referrals directly to:
Eric Whitman, M.D.
Main telephone: (973) 971-7111
100 Madison Avenue, Floor 2
Morristown, NJ 07960
OHSU
New Patient Coordinator:
Brandon Labadie labadie@ohsu.edu (971) 337-6316
Patient referrals directly to:
Marcel E. Curlin, M.D.
Main telephone: (503) 494-4971
3270 SW Pavilion Loop
Physicians Pavilion
Suite 320
Portland, OR 97239
Ohio Health
New Patient Coordinator:
Amanda Brown amanda.brown2@ohiohealth.org (614) 788-3884
Patient referrals directly to:
Kiran K. Devulapally, M.D.
Main telephone: (614) 293-4925
2050 Kenny Road
Suite 2200
Columbus, OH 43221
Center for Advanced Research & Education
New Patient Coordinator:
Angela Ritter, M.D. angela.ritter@nghs.com
Patient referrals directly to:
Angela Ritter, M.D.
Main telephone: (770) 848-9052
4754 Martin Road
Flowery Branch, GA 30542
Holy Name Medical Center
New Patient Coordinator:
Patty Kiledjian pkiledjian@holyname.org (201) 541-6312
Patient referrals directly to:
Benjamin De La Rosa, M.D.
Main telephone: (201) 833-3280
718 Teaneck Road
Teaneck, NJ 07666
St. Jude Medical Center
New Patient Coordinator:
Bianca Sanchez bianca.sanchez@stjoe.org
(714) 992-3000 x5620
Patient referrals directly to:
David Park, M.D.
Main telephone: (714) 446-7181
2151 North Harbor Boulevard
Fullerton, CA 92835
Baylor College of Medicine
New Patient Coordinator:
Hinali Zaver hzaveri@bcm.edu (713) 873-2353
Patient referrals directly to:
Kalpalatha Guntupalli, M.D.
Main telephone: (713) 798-2500
6620 Main Street
Houston, TX 77030
Phase 2 Trial for Patients with Mild to Moderate Coronavirus Disease:
For information about enrolling in our Phase 2 trial for patients with Mild to Moderate Coronavirus disease, please contact:
Montefiore Medical Center
New Patient Coordinators:
Pam Philippsborn at (718) 920-5864
Reena Joseph at (718) 920 5864
Jasmine Thalappillil at (718) 920-5864
Patient referrals directly to:
Harish Seethamraju, M.D.
Main telephone: (718) 920-5864
3400 Bainbridge Avenue
Bronx, NY 10467
Novant Health
New Patient Coordinators:
Kathleen O’Brien kathleen.obrien@novanthealth.org (704) 996-7627
Pailing Richards pcrichards@novanthealth.org (704) 996-7627
Patient referrals directly to:
Michael Morgan, M.D.
Main telephone: (336) 718-0440
1381 Westgate Center Dr
Winston-Salem, NC 27103
UCLA Medical Center
New Patient Coordinator:
Nancy Lopez nancyrlopez@mednet.ucla.edu (310) 794-8043
Patient referrals directly to:
Otto Yang, M.D.
Main telephone: (310) 206-7663
200 Medical Plaza Driveway
Los Angeles, CA 90095
Palmtree Clinical Research
New Patient Coordinators:
Shayna Phillips at (760) 778-7799
Daniel Rangel at (760) 778-7799
Carlos Martinez, M.D. at (760) 778-7799
Patient referrals directly to:
Carlos Martinez, M.D.
Main telephone: (760) 778-7799
555 E. Tachevah Drive, Suite 1E-201
Palm Springs, CA 92262
Center for Advanced Research & Education
New Patient Coordinator:
Angela Ritter, M.D. angela.ritter@nghs.com
Patient referrals directly to:
Angela Ritter, M.D.
Main telephone: (770) 848-9052
4754 Martin Road
Flowery Branch, GA 30542
Yale
New Patient Coordinator:
Jackie Baron jackie.baron@yale.edu (203) 737-4040
Patient referrals directly to:
Onyema Ogbuagu, MBBCh, FACP
Main telephone: (203) 688-5303
20 York Street
New Haven, CT 06510
Eisenhower Health
New Patient Coordinator:
Stephanie Farrell sfarrell@eisenhowerhealth.org (760) 674-3644
Patient referrals directly to:
Kenneth Lichtenstein, M.D.
Main telephone: (760) 834-7950
4791 East Palm Canyon Drive
Palm Springs, CA 92264
Atlantic Health
New Patient Coordinator:
Kathryn Radler kathryn.radler@atlantichealth.org (908) 522-4899
Patient referrals directly to:
Eric Whitman, M.D.
Main telephone: (973) 971-7111
100 Madison Avenue, Floor 2
Morristown, NJ 07960
White Plains Hospital
New Patient Coordinator:
Lisa La lla1@wphospital.org (914) 849-7429
Patient referrals directly to:
Daniel Sammartino, M.D.
Main telephone: (914) 849-7600
2 Longview Ave
White Plains, NY 10601
Beth Israel Deaconess Medical Center – Harvard Medical School
New Patient Coordinator:
Caitlin Davis cdavis6@bidmc.harvard.edu (617) 735-4466
Patient referrals directly to:
Chen S. Tan, M.D.
Main telephone: (617) 632-7706
110 Francis Street, Lowry GB
Boston, MA 02215-5501
Misiu
You are amazing! Just when after 10 years I really thought about walking away but you are totally correct. Hey I remember .26 cents and we made it to 10 we will do it again. I can understand Nadar's frustration but I am going to buy more on dips.
The Wall Street article is total BS
Grip
Glad to see you happy
Mark this Leronlimab will not cure the virus but it will keep you from dying.
Amatuer17
I have been in CTDY for 11 years and 3.8 million shares. I totally stay on top of everything but you are totally misinformed. I promise you that you are really misinformed.
Chump
Hey You are the man, we can always count on you thank you for all your hard work.
Great Post Blane
I agree with you. So stupid to ask about a business plan. Also, I have a group of people that meet and converse after the call and they wanted me to tell Grip he has way to much time on his hands. LOL
GRIP IN A NICE WAY MY FRIEND
YOU ARE WAY TO NEGATIVE.
I know many don't really care but ever happened to Finesand?
I just wondered if she was Short CYDY and maybe lost everything. This person posted every 15 minutes and just disappeared around the time good news was coming in
Grip and Saltz
The OTCBB is run by market Makers it's a scam used by DTC
Ok, this guy Tom with his Company believes CYDY has 150,000,000 phantom short. This is why all the firms will not let us trade any OTCBB. I have been a broker for 40 years. In order for this to change we have to have incredible news or get bought out.
See his email to me today
Dear CYDY Investor Relations:
Here is your Buyins.net RegSHO Compliance Alert for January 22nd, 2020. Our RegSHO Compliance Service helps to protect CYDY from short sellers and market makers that are violating the more stringent RegSHO market integrity provisions recently enacted. We are monitoring the trading activity in CYDY and here is today's report:
Total Trading Volume: 2974663
Daily Short Volume: 1425364
Avg. Price of Shorts Today: 1.086
Short %: 47.92
Volume at Offer: 1376745
Buy%: 46.28
Volume at Bid: 1595380
Sell%: 53.63
Shares Crossed: 2538
Cross%: 0.09
Net Buying vs. Selling: -218635
Price Change: 0.02
Friction Factor: 0
The above data is used to calculate if a fair market is being made in the shares of CYDY. Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. Today, your Friction Factor was 0. Here is how to understand Friction Factor:
1. If Friction Factor is positive, more buying than selling caused CYDY's price to rise
2. If Friction Factor is negative, more selling than buying caused CYDY's price to fall
3. If Friction Factor is 0, there was no discernable activity either way
4. If Friction Factor is abnormal, it means that more buying than selling caused the price to drop, which is evidence of manipulative activity. In some cases more selling than buying can cause the price to increase. While this is rare, it must be noted as well.
By signing up for our RegSHO Compliance Service, we will monitor your trading daily and identify short selling, illegal short selling, manipulative market maker activity and alert the media when a short squeeze begins and when forced buy-ins occur because we were able to get broker dealers, FINRA or the SEC to force �buy to covers� upon short sellers that have not located, borrowed and delivered shares shorted by T+3.
Here are our unique data sources:
1. Nightly Threshold Security Lists ("Naked Short Lists"): data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
2. Daily Size of Failures to Deliver ("Size of Naked Shorts on a day to day basis): directly from SEC
3. Daily Short Sales Times and Sales Data: data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
4. Brokerage firms that trades go through: data comes directly from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges
5. Names and positions of short sellers with assets under management exceeding $100 million: data will come directly from SEC
6. Blue Sheet Data Requests: We deal directly with FINRA and SEC to alert them as to which stocks and which brokerage firms SEC and FINRA need to investigate.
7. Trading Statistics and Friction Factor are based on data provided by all US stock exchanges and proprietary analysis of the activity.
The data we provide is extremely useful for CYDY for the following reasons:
1. Stop naked short selling in the company you are covering
2. Break the market maker hold on Level II box causing so much price friction
3. Our SqueezeTrigger Reports that cross newswires and are sent to our 720,000 users help break the rest of the shorts
4. Discourage new short sellers from shorting your stock
5. Stop the negative perception that dropping stock price places on normal day to day business operations
6. Combined all of these facets help to stop the daily drain that the short attacks have on the company.
Please call us for details.
Tom Ronk, RIA, CTA
Founder & CEO
Newport Beach, CA
tom@buyins.net
1-949-230-7680
https://wopr.buyins.net/
READ ON
However, the research has been tested only in animals and on cells in the laboratory, and more safety checks would be needed before human trials could start.
Venus1 you are so right! Nadar has a plan and it's not a buyout.....it will be about 32 partnerships.....
1. HIV cash and 50%
2. Breast Cancer Cash +50%
3. Colon Cancer cash + 50%
4. CytoDyn announced it will begin 8 pre-clinical studies on melanoma cancer, pancreatic, breast, prostate, colon, lung, liver, and stomach cancer.
$500.00 a share is not crazy!
Better to read than listen to the Gothic lady
https://marketnewsfirst.com/primo-nutraceuticals/f/the-billion-dollar-race-in-metastatic-breast-cancer
100% chance of positive news I have a feeling...
Should be a great week ahead
FOR WHAT'S IT WORTH
Dear CYDY Investor Relations:
Here is your Buyins.net RegSHO Compliance Alert for December 19th, 2019. Our RegSHO Compliance Service helps to protect CYDY from short sellers and market makers that are violating the more stringent RegSHO market integrity provisions recently enacted. We are monitoring the trading activity in CYDY and here is today's report:
Total Trading Volume: 9052674
Daily Short Volume: 4872796
Avg. Price of Shorts Today: 0.58
Short %: 53.83
Volume at Offer: 4912470
Buy%: 54.27
Volume at Bid: 4138062
Sell%: 45.71
Shares Crossed: 2142
Cross%: 0.02
Net Buying vs. Selling: 774408
Price Change: 0.218
Friction Factor: 35523.30275
The above data is used to calculate if a fair market is being made in the shares of CYDY. Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. Today, your Friction Factor was 35523.30275. Here is how to understand Friction Factor:
1. If Friction Factor is positive, more buying than selling caused CYDY's price to rise
2. If Friction Factor is negative, more selling than buying caused CYDY's price to fall
3. If Friction Factor is 0, there was no discernable activity either way
4. If Friction Factor is abnormal, it means that more buying than selling caused the price to drop, which is evidence of manipulative activity. In some cases more selling than buying can cause the price to increase. While this is rare, it must be noted as well.
By signing up for our RegSHO Compliance Service, we will monitor your trading daily and identify short selling, illegal short selling, manipulative market maker activity and alert the media when a short squeeze begins and when forced buy-ins occur because we were able to get broker dealers, FINRA or the SEC to force �buy to covers� upon short sellers that have not located, borrowed and delivered shares shorted by T+3.
Here are our unique data sources:
1. Nightly Threshold Security Lists ("Naked Short Lists"): data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
2. Daily Size of Failures to Deliver ("Size of Naked Shorts on a day to day basis): directly from SEC
3. Daily Short Sales Times and Sales Data: data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
4. Brokerage firms that trades go through: data comes directly from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges
5. Names and positions of short sellers with assets under management exceeding $100 million: data will come directly from SEC
6. Blue Sheet Data Requests: We deal directly with FINRA and SEC to alert them as to which stocks and which brokerage firms SEC and FINRA need to investigate.
7. Trading Statistics and Friction Factor are based on data provided by all US stock exchanges and proprietary analysis of the activity.
The data we provide is extremely useful for CYDY for the following reasons:
1. Stop naked short selling in the company you are covering
2. Break the market maker hold on Level II box causing so much price friction
3. Our SqueezeTrigger Reports that cross newswires and are sent to our 720,000 users help break the rest of the shorts
4. Discourage new short sellers from shorting your stock
5. Stop the negative perception that dropping stock price places on normal day to day business operations
6. Combined all of these facets help to stop the daily drain that the short attacks have on the company.
Please call us for details.
Tom Ronk, RIA, CTA
Founder & CEO
Newport Beach, CA
You Amateur 17
You have no idea what is ahead!!
No idea!!
I agree we have tried to tell Grip and help him. That Dr. Pastell is one bad dude and it will come out. Mark my word on this. See all of you in Vegas!
Happy Thanksgiving Grip
Dolly Parton said it best
"If you want a Rainbow you gotta put up with the Rain!"
This will be the best week of our life!!!!!
I have a question for anyone that can answer. What if Cytodyn announced to the investment community that Leronlimab {PRO 140} stops the metastasis of cancer. No, sarcasm please what would happen to the stock?
I am very serious about this question. I have so many friends that are very sick with all types of cancer.
Would it hit the national news?
Would BP go crazy getting a piece of the action?
Please be serious
Grip
For what it's worth I have been a large shareholder of Cytodyn and in for 9 years. You are really totally wrong with your assessment of NP. I know the email is factual. I promise you that I have done my due diligence and in the end, we will all be in Vegas very shortly but I will reiterate you are totally wrong about Nadar. Best of luck.
JNJ halted trading
That's easy Nadar owns stock and has a vested interest. I do not know Mr. Grip but the way he talks it's like he wants this to fail
All of you have no idea what is going on. The Board of Directors loves Nadar, If you don't know for sure then add that at the end of your post.
I KNOW FOR SURE!
Very Interesting call today. One thing I was very happy to hear is that the licensing deal is still alive and kicking...And it looks like he is under a huge NDA and cannot talk because there is new competition for our drug. This is a very slow process dealing with the FDA but I think I see us getting closer.
ESTATE SALE
CLIENT DIED AND FAMILY SAID SELL ALL OF THE STOCKS!
OH WELL
Finesand
Goldman Sachs has been involved for over two years... NP and been in many meetings with GS. RP never brought GS to the table, it was NP!
That is a great Question
I am curious where do most of you trade or buy CYDY? I have a reason for this so, please take a minute and tell me which company, like Schwab, Etrade, etc.
AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill
https://www.statnews.com/pharmalot/2019/08/19/gilead-hiv-aids-truvada-congress/
Thank You Amatuer17
I have read most of your posts and I have come to the conclusion that I should sell all my CYDY today. Can you give me a good reason to keep it?
Thank you so much for your wisdom!
RP is a Research Physician and not a Clinical Physician, he never had the skills to get the Triple Negative Breast Cancer off the ground. NP told him that was his only job was to get that to the finish line. NP was handling HIV. RP wanted to be the President and CEO. It would be like Albert Einstien running General Electric. I think there was a coup d'état and the Board showed him the door. He has plenty of stock and knows we have the crown jewel in Leronlimab.
FINISH END OF STORY
MY THINKING IS THAT THEY WERE BOTH FIGHTING OVER WHO WOULD WIN THE NOBEL PRIZE FOR MEDICINE. 9 MILLION AWARD. SIT BACK AND ENJOY THE NEXT FEW WEEKS
I WILL SEE ALL OF YOU IN VEGAS
SPOT ON CHUMP
Dear CYDY Investor Relations:
Here is your Buyins.net RegSHO Compliance Alert for July 18th, 2019. Our RegSHO Compliance Service helps to protect CYDY from short sellers and market makers that are violating the more stringent RegSHO market integrity provisions recently enacted. We are monitoring the trading activity in CYDY and here is today's report:
Total Trading Volume: 993753
Daily Short Volume: 659131
Avg. Price of Shorts Today: 0.447
Short %: 66.33
Volume at Offer: 374382
Buy%: 37.67
Volume at Bid: 619069
Sell%: 62.3
Shares Crossed: 302
Cross%: 0.03
Net Buying vs. Selling: -244687
Price Change: 0.0293
Friction Factor: 0
The above data is used to calculate if a fair market is being made in the shares of CYDY. Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. Today, your Friction Factor was 0. Here is how to understand Friction Factor:
1. If Friction Factor is positive, more buying than selling caused CYDY's price to rise
2. If Friction Factor is negative, more selling than buying caused CYDY's price to fall
3. If Friction Factor is 0, there was no discernable activity either way
4. If Friction Factor is abnormal, it means that more buying than selling caused the price to drop, which is evidence of manipulative activity. In some cases more selling than buying can cause the price to increase. While this is rare, it must be noted as well.
By signing up for our RegSHO Compliance Service, we will monitor your trading daily and identify short selling, illegal short selling, manipulative market maker activity and alert the media when a short squeeze begins and when forced buy-ins occur because we were able to get broker dealers, FINRA or the SEC to force �buy to covers� upon short sellers that have not located, borrowed and delivered shares shorted by T+3.
Here are our unique data sources:
1. Nightly Threshold Security Lists ("Naked Short Lists"): data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
2. Daily Size of Failures to Deliver ("Size of Naked Shorts on a day to day basis): directly from SEC
3. Daily Short Sales Times and Sales Data: data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
4. Brokerage firms that trades go through: data comes directly from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges
5. Names and positions of short sellers with assets under management exceeding $100 million: data will come directly from SEC
6. Blue Sheet Data Requests: We deal directly with FINRA and SEC to alert them as to which stocks and which brokerage firms SEC and FINRA need to investigate.
7. Trading Statistics and Friction Factor are based on data provided by all US stock exchanges and proprietary analysis of the activity.
The data we provide is extremely useful for CYDY for the following reasons:
1. Stop naked short selling in the company you are covering
2. Break the market maker hold on Level II box causing so much price friction
3. Our SqueezeTrigger Reports that cross newswires and are sent to our 720,000 users help break the rest of the shorts
4. Discourage new short sellers from shorting your stock
5. Stop the negative perception that dropping stock price places on normal day to day business operations
6. Combined all of these facets help to stop the daily drain that the short attacks have on the company.
Please call us for details.
Tom Ronk, RIA, CTA
Founder & CEO
Newport Beach, CA
tom@buyins.net
1-949-230-7680
https://wopr.buyins.net/
. I AM EXTREMELY POSITIVE THAT 10 IS A LOW NUMBER, 50 MEDIUM, AND 200 HIGH
Please understand Dr. P is a man of God, He is an amazing person and you should read his books. You will understand his drive for humankind.
https://www.amazon.com/Corruption-Moslem-Minds-Nader-Pourhassan/dp/097119307X